AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29354921 — intervention group
Group type: EXPERIMENTAL
Intervention: Scraping therapy (4 sessions over 4 weeks)
Number of subjects: 80
Study 29354921 — intervention group
Group type: EXPERIMENTAL
Intervention: Scraping therapy (lung qi deficiency and cold group)
Number of subjects: 80
Study 29354921 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (10 mg, once a day for 4 weeks)
Number of subjects: 80
Study 25601933 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 6 months
Number of subjects: 117
Study 25601933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 117
Study 25601933 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment (per-protocol analysis)
Number of subjects: 117
Study 25601933 — intervention group
Group type: COMPARATOR
Intervention: Control group (per-protocol analysis)
Number of subjects: 117
Study 25401208 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-focused relaxation group (38 subjects)
Number of subjects: 112
Study 25401208 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and video group (35 subjects)
Number of subjects: 112
Study 25401208 — intervention group
Group type: COMPARATOR
Intervention: Control group (39 subjects)
Number of subjects: 112
Study 22447547 — intervention group
Group type: EXPERIMENTAL
Intervention: TISSEEL (fibrin glue)
Number of subjects: 43
Study 22447547 — intervention group
Group type: COMPARATOR
Intervention: Vicryl 8‐0 sutures
Number of subjects: 43
Study 20711439 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heat therapy
Number of subjects: 34
Study 20711439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 34
Study 20711439 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast therapy
Number of subjects: 34
Study 20711439 — intervention group
Group type: COMPARATOR
Intervention: Heating pad (control)
Number of subjects: 34
Study 17394940 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 45 mg orally three times daily
Number of subjects: 169
Study 17394940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 16287453 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 2 weeks
Number of subjects: 64
Study 16287453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12011810 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention by nurses providing information and support, 6 calls over 7 weeks
Number of subjects: 131
Study 12011810 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 131
Study 10027102 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 37
Study 10027102 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 37
Study 10027102 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone + aminoglycoside
Number of subjects: 37
Study 8907444 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeled walking aid
Number of subjects: 11
Study 1872346 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support between enrollment at +/‐ 20 weeks and delivery at +/‐ 38 weeks
Number of subjects: 86
Study 1872346 — intervention group
Group type: COMPARATOR
Intervention: Standard care at the antenatal clinic
Number of subjects: 86
Study 6214234 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 12
Study 6214234 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine hydrochloride
Number of subjects: 12
Study 29902061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shuttle Walk Test (MSWT) after 16 weeks of aerobic exercise intervention
Number of subjects: 248
Study 29902061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shuttle Walk Test (MSWT) in obese participants (N=128)
Number of subjects: 248
Study 29902061 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of measured and predicted V̇O2peak at follow-up
Number of subjects: 248
Study 28333362 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide multimatrix 9 mg
Number of subjects: 510
Study 28333362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 26600646 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Oral Examination (SOE)
Number of subjects: 123
Study 26600646 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oral Examination (COE)
Number of subjects: 123
Study 23924446 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravesical instillation of Pirarubicin (THP) 30 mg/50 ml within 24 hours post TUR, followed by regular instillations once a week for 8 weeks, then once a month for 1 year.
Number of subjects: 403
Study 23924446 — intervention group
Group type: COMPARATOR
Intervention: Regular intravesical therapy only.
Number of subjects: 403
Study 23924446 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravesical instillation of Pirarubicin (THP) for low and intermediate-risk patients.
Number of subjects: 403
Study 23924446 — intervention group
Group type: COMPARATOR
Intervention: Regular intravesical therapy only for low and intermediate-risk patients.
Number of subjects: 403
Study 23924446 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravesical instillation of Pirarubicin (THP) for high-risk patients.
Number of subjects: 403
Study 23924446 — intervention group
Group type: COMPARATOR
Intervention: Regular intravesical therapy only for high-risk patients.
Number of subjects: 403
Study 21922971 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoStase
Number of subjects: 18
Study 21922971 — intervention group
Group type: COMPARATOR
Intervention: FloSeal
Number of subjects: 18
Study 19589565 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg followed by 200 mg every 12 hours for 10 days
Number of subjects: 53
Study 19589565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19589565 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 53
Study 16919541 — intervention group
Group type: COMPARATOR
Intervention: HI OA diet (fat, 40%; PA, 1.7%; OA, 31.4%)
Number of subjects: 19
Study 16919541 — intervention group
Group type: EXPERIMENTAL
Intervention: HI PA diet (fat, 40%; PA, 16.8%; OA, 16.4%)
Number of subjects: 19
Study 16919541 — intervention group
Group type: COMPARATOR
Intervention: HI OA diet
Number of subjects: 19
Study 16919541 — intervention group
Group type: EXPERIMENTAL
Intervention: HI PA diet
Number of subjects: 19
Study 15585427 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention (10-session training)
Number of subjects: 156
Study 11385230 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin 600 mg twice daily for 12 months
Number of subjects: 59
Study 11385230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 4 months
Number of subjects: 59
Study 11385230 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole pulse therapy (200 mg twice daily for 1 week with 3 weeks off between pulses)
Number of subjects: 59
Study 11385230 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg daily for 12 weeks
Number of subjects: 59
Study 11385230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg daily for 12 weeks
Number of subjects: 59
Study 1443356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g intramuscular (i.m.) 1 hour preoperatively and a second dose 1 hour before catheter removal (Study 1)
Number of subjects: 139
Study 1443356 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 1 g i.m. 1 hour preoperatively (Study 2)
Number of subjects: 139
Study 1443356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g i.m. 1 hour before catheter removal (Study 2)
Number of subjects: 139
Study 6399346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy
Number of subjects: 76
Study 6399346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium therapy)
Number of subjects: 76
Study 6399346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy (subgroup without heart failure)
Number of subjects: 76
Study 6399346 — intervention group
Group type: COMPARATOR
Intervention: Control group (subgroup without heart failure)
Number of subjects: 76
Study 29532734 — intervention group
Group type: EXPERIMENTAL
Intervention: sirukumab 50 mg every 4 weeks (q4w)
Number of subjects: 116
Study 29532734 — intervention group
Group type: EXPERIMENTAL
Intervention: sirukumab 100 mg every 2 weeks (q2w)
Number of subjects: 116
Study 29532734 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study 29532734 — intervention group
Group type: EXPERIMENTAL
Intervention: sirukumab 50 mg q4w
Number of subjects: 116
Study 29532734 — intervention group
Group type: EXPERIMENTAL
Intervention: sirukumab 100 mg q2w
Number of subjects: 116
Study 29532734 — intervention group
Group type: EXPERIMENTAL
Intervention: sirukumab combined groups
Number of subjects: 116
Study 29436152 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet hemodialysis session (immersion in 34 to 35°C bath)
Number of subjects: 10
Study 29436152 — intervention group
Group type: COMPARATOR
Intervention: Dry hemodialysis session (standard hemodialysis)
Number of subjects: 10
Study 29436152 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet hemodialysis session
Number of subjects: 10
Study 29436152 — intervention group
Group type: COMPARATOR
Intervention: Dry hemodialysis session
Number of subjects: 10
Study 29436152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sessions
Number of subjects: 10
Study 27418379 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral ultrabrief pulse ECT combined with venlafaxine
Number of subjects: 240
Study 27418379 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 240
Study 25124976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration ≥10 hours
Number of subjects: 143
Study 25124976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration 9–10 hours
Number of subjects: 143
Study 25124976 — intervention group
Group type: COMPARATOR
Intervention: Sleep duration <9 hours
Number of subjects: 143
Study 22773291 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy group (PG) - 15 minutes of daily passive movements with gentle joint compression 5 days a week
Number of subjects: 30
Study 22773291 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 19965548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet plus low-dose calcitriol analogs (Cinacalcet-D)
Number of subjects: 91
Study 19965548 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol analogs alone (Flex-D)
Number of subjects: 91
Study 18664988 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin/erythromycin therapy at school for positive throat cultures
Number of subjects: 0
Study 18664988 — intervention group
Group type: COMPARATOR
Intervention: Control group sought medical care from their regular provider
Number of subjects: 0
Study 15882245 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, tinidazole, and esomeprazole (Group MTE)
Number of subjects: 320
Study 15882245 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, amoxicillin, and esomeprazole (Group MAE)
Number of subjects: 320
Study 15882245 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy with clarithromycin, amoxicillin, and esomeprazole (Group CAE)
Number of subjects: 320
Study 15882245 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy with tinidazole (Group CTE)
Number of subjects: 320
Study 12963604 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.3% ciprofloxacin solution or ointment
Number of subjects: 663
Study 15321076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg subarachnoid diamorphine
Number of subjects: 60
Study 15321076 — intervention group
Group type: COMPARATOR
Intervention: 3 mg epidural diamorphine
Number of subjects: 60
Study 8675360 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (renal hypoperfusion)
Number of subjects: 27
Study 8675360 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine urea excretion indices
Number of subjects: 27
Study 1677616 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SST)
Number of subjects: 30
Study 1677616 — intervention group
Group type: COMPARATOR
Intervention: Control (no SST)
Number of subjects: 30
Study 3893776 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine single dose of 10 mg/kg
Number of subjects: 109
Study 3893776 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine full dose of 25 mg/kg
Number of subjects: 109
Study 3893776 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro tests
Number of subjects: 109
Study 29777297 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) performed at the end of procedure
Number of subjects: 54
Study 29777297 — intervention group
Group type: EXPERIMENTAL
Intervention: High verapamil administration (18%)
Number of subjects: 54
Study 27119576 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg, single dose) with omeprazole (40 mg q.d.)
Number of subjects: 79
Study 27119576 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg, single dose) with metformin (1000 mg q.d.)
Number of subjects: 79
Study 27119576 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg, single dose) with levonorgestrel-ethinyl estradiol (150/30 μg single dose)
Number of subjects: 79
Study 24621518 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VR condition
Number of subjects: 69
Study 24621518 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive VR condition
Number of subjects: 69
Study 24621518 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 69
Study 25008950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/day)
Number of subjects: 42
Study 25008950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21460332 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Provider Alliance Program
Number of subjects: 275
Study 21460332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 275
Study 18094224 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg alone
Number of subjects: 28
Study 18094224 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg alone
Number of subjects: 28
Study 18094224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg followed by aspirin 325 mg 2 hours later
Number of subjects: 28
Study 18094224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with NSAID (ibuprofen or naproxen)
Number of subjects: 28
Study 16188909 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT-adapt diet
Number of subjects: 7
Study 16188909 — intervention group
Group type: COMPARATOR
Intervention: HCHO diet
Number of subjects: 7
Study 14561562 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention for mothers
Number of subjects: 0
Study 14561562 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers not receiving the intervention)
Number of subjects: 0
Study 10901564 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labour (n = 320)
Number of subjects: 651
Study 10901564 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 331)
Number of subjects: 651
Study 8835705 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (150 mg daily)
Number of subjects: 30
Study 8835705 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (Fluv)
Number of subjects: 30
Study 1596968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml.kg‐1 bupivacaine 0.125% with 1:200,000 epinephrine
Number of subjects: 80
Study 1596968 — intervention group
Group type: COMPARATOR
Intervention: 1 ml.kg‐1 bupivacaine 0.125% with 1:200,000 epinephrine
Number of subjects: 80
Study 6431130 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone elastomer (SE) catheters
Number of subjects: 75
Study 6431130 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane (PU) catheters
Number of subjects: 75
Study 6431130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SE and PU catheters
Number of subjects: 75
Study 31248843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug group (cyclosporine, mycophenolate mofetil, and sirolimus)
Number of subjects: 167
Study 31248843 — intervention group
Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis group (cyclosporine and mycophenolate mofetil)
Number of subjects: 167
Study 31248843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug group
Number of subjects: 167
Study 31248843 — intervention group
Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis group
Number of subjects: 167
Study 29102441 — intervention group
Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A (Btx) - 100 UI in Flexor digitorum brevis
Number of subjects: 45
Study 29102441 — intervention group
Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A (Btx) - 100 UI in Flexor digitorum longus
Number of subjects: 45
Study 29102441 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Flexor digitorum longus and Flexor digitorum brevis
Number of subjects: 45
Study 29102441 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 2 injections
Number of subjects: 45
Study 26949119 — intervention group
Group type: EXPERIMENTAL
Intervention: Study eyes with manifest glaucoma
Number of subjects: 249
Study 26949119 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes without visual field loss
Number of subjects: 249
Study 24996030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick protein (DSP)
Number of subjects: 4211
Study 24996030 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific gravity (SG)
Number of subjects: 4211
Study 24996030 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation 1
Number of subjects: 4211
Study 24996030 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation 2
Number of subjects: 4211
Study 24996030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DSP and SG with ALB
Number of subjects: 4211
Study 22520142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 5468
Study 20473067 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 724
Study 20473067 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant therapy alone (Control)
Number of subjects: 724
Study 17912124 — intervention group
Group type: EXPERIMENTAL
Intervention: BRYAN Cervical Disc Prosthesis
Number of subjects: 115
Study 17912124 — intervention group
Group type: COMPARATOR
Intervention: ACDF (Control group)
Number of subjects: 115
Study 16126016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral daily ibandronate (2.5 mg)
Number of subjects: 1964
Study 16126016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1964
Study 11874442 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sibutramine bid
Number of subjects: 150
Study 11874442 — intervention group
Group type: COMPARATOR
Intervention: 120 mg orlistat tid
Number of subjects: 150
Study 11874442 — intervention group
Group type: COMPARATOR
Intervention: 850 mg metformin bid
Number of subjects: 150
Study 10440605 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg or 10 mg)
Number of subjects: 567
Study 10440605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 7560246 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-CRS (controlled-release suppository)
Number of subjects: 10
Study 7560246 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous morphine
Number of subjects: 10
Study 2185342 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy
Number of subjects: 0
Study 6938013 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diethylstilbestrol (DES) daily by mouth
Number of subjects: 0
Study 6938013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6938013 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus radical prostatectomy
Number of subjects: 0
Study 31134731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT-T) delivered by trainee psychologists
Number of subjects: 52
Study 31134731 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (4-week wait period)
Number of subjects: 52
Study 28880609 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued use of antipsychotics
Number of subjects: 67
Study 28880609 — intervention group
Group type: COMPARATOR
Intervention: Continued use of antipsychotics
Number of subjects: 67
Study 25478740 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) tool for classification of pulmonary nodules
Number of subjects: 150
Study 25478740 — intervention group
Group type: COMPARATOR
Intervention: Human expert classification
Number of subjects: 150
Study 24065920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 77
Study 21720181 — intervention group
Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 1223
Study 19249182 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg infused over 1 h every 8 h for complicated intra-abdominal infections
Number of subjects: 0
Study 19249182 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg infused over 4 h every 8 h for hospital-acquired pneumonia
Number of subjects: 0
Study 16199079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel
Number of subjects: 686
Study 16199079 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 686
Study 12957743 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 750 mg daily in divided doses for 14 days
Number of subjects: 30
Study 11244516 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA)
Number of subjects: 0
Study 11244516 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 11244516 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherectomy before Multilink Stent
Number of subjects: 0
Study 10168581 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0